New GlyT2 blocker relieves chronic neuropathic pain without major side effects

Chronic neuropathic pain remains one of the most challenging conditions to treat, with current therapies offering limited benefit and being over-reliant on opioids. Researchers at Rensselaer Polytechnic Institute (RPI), along with collaborators from the University of Sydney and the University of Copenhagen, have developed an approach that offers a clearer path toward safer, non-addictive pain therapies.